Show simple item record

dc.contributor.authorAssemblée mondiale de la Santé, 16
dc.date.accessioned2015-09-16T14:04:23Z
dc.date.available2015-09-16T14:04:23Z
dc.date.issued1963
dc.identifier.govdocA16/21
dc.identifier.urihttps://iris.who.int/handle/10665/184619
dc.language.isofren_US
dc.publisherOrganisation mondiale de la Santéen_US
dc.subjectInternational Health Regulationsen_US
dc.subjectPharmaceutical productsen_US
dc.subject.meshCommunicable Disease Controlen_US
dc.subject.meshDisease Outbreaksen_US
dc.subject.meshSanitationen_US
dc.subject.meshDisease Notificationen_US
dc.subject.meshQuarantineen_US
dc.subject.meshPharmaceutical Preparationsen_US
dc.subject.meshDrug Evaluationen_US
dc.subject.meshSubstance-Related Disordersen_US
dc.titleCinquième rapport de la Commission du Programme et du Budgeten_US
dc.typeGoverning body documentsen_US
dc.subject.meshqualifierprevention and controlen_US


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record